HOME > INTERVIEW

INTERVIEW

Takeda’s Japan Biz “Going in Good Direction” towards 1st Underlying Sales Rise in 5 Years: Iwasaki

February 24, 2017
CEO Weber Says Takeda’s Ongoing Transformation “Irreversible”: Full Interview

February 8, 2017
MHLW’s Sakoi Calls on Industry to Transcend Corporate Boundaries, Join Pricing Reform Debate

January 16, 2017
Interview: Metgluco, AGs, and Diagnostics 3 Biz Pillars for New Sumitomo Dainippon Subsidiary

December 2, 2016
Interview: Ex-Astellas Boss Takenaka Urges Mid-Size Makers to Be More Open to Academia in Pathological Research

August 18, 2016
Japan Biosimilar Association Aims to Share Knowledge and Experience to Popularize the Use of Biosimilars: Director General

August 5, 2016
Takeda Linking Arms with a “Reborn” Teva, Sees Turning Point in Market as an Opportunity: Japan Biz Chief Iwasaki

March 30, 2016
Takeda Aims to Return to Growth Track in FY2016, Sales Head Confident in Takecab

March 23, 2015
EFPIA Japan Chairman Says Drug Costs Won’t Explode

January 14, 2015
Gilead Starting from Scratch to Build Solo Sales Regime: Japan Pres.

November 28, 2014

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…